Cosopt and eyelid margin crusting Patient Reports February 11, 2012

Cosopt Side Effects Report #5370058-4
Cosopt side effect was reported by a Physician from UNITED STATES on Aug 08, 2006. Female patient, 81 years of age, was diagnosed with glaucoma  and was treated with Cosopt. After drug was administered, patient experienced the following side effects: back pain , eye discharge, eyelid margin crusting. Cosopt dosage: unknown. During the same period patient was treated with ALPHAGAN, XALATAN. Patient recovered.

Cosopt Side Effects Report #5494710-5
Cosopt side effect was reported by a Physician from UNITED STATES on Oct 19, 2007. Female patient, 81 years of age, was diagnosed with glaucoma  and was treated with Cosopt. After drug was administered, patient experienced the following side effects: back pain , eye discharge, eyelid margin crusting, glaucoma , thrombosis. Cosopt dosage: unknown. During the same period patient was treated with XALATAN, ALPHAGAN. Patient recovered.

Cosopt Side Effects Report #5507806-6
Cosopt side effect was reported by a Physician from UNITED STATES on Oct 26, 2007. Female patient, 81 years of age, was diagnosed with glaucoma  and was treated with Cosopt. After drug was administered, patient experienced the following side effects: arthritis , back pain , dacryostenosis acquired, eye discharge, eyelid margin crusting, glaucoma , musculoskeletal stiffness, rectal haemorrhage, thrombosis. Cosopt dosage: unknown. During the same period patient was treated with XALATAN, ALPHAGAN, ASPIRIN, OMEGA. Patient recovered.

Cosopt Side Effects Report #4971881-8
Cosopt side effect was reported by a Pharmacist from UNITED STATES on Apr 04, 2006. Male patient, 71 years of age, was diagnosed with glaucoma  and was treated with Cosopt. After drug was administered, patient experienced the following side effects: eyelid margin crusting, eyelid oedema, lacrimation increased, scab . Cosopt dosage: unknown. During the same period patient was treated with ATENOLOL, ATIVAN, REMERON, ASPIRIN. Patient recovered.